SRT 3025 is an activator of sirtuin 1 (SIRT1).1,2,3 It increases SIRT1 levels in, and inhibits RANKL-induced osteoclastogenesis of, mouse bone marrow-derived macrophages (BMDMs) when used at a concentration of 2 ?M.1 SRT 3025 inhibits the proliferation of SU.86.86 pancreatic adenocarcinoma cells (IC50 = 0.98 ?M).2 It decreases plasma levels of LDL, VLDL, and total cholesterol in ApoE-/- mice fed a high-cholesterol diet when administered at a dose of 3.18 g/kg.3
1.Gurt, I., Artsi, H., Cohen-Kfir, E., et al.The Sirt1 activators SRT2183 and SRT3025 Inhibit RANKL-induced osteoclastogenesis in bone marrow-derived macrophages and down-regulate Sirt3 in Sirt1 null cellsPLoS One10(7)e0134391(2015) 2.Chini, C.C.S., Espindola-Netto, J.M., Mondal, G., et al.SIRT1-activating compounds (STAC) negatively regulate pancreatic cancer cell growth and viability through a SIRT1 lysosomal-dependent pathwayClin. Cancer Res.22(10)2496-2507(2015) 3.Miranda, M.X., van Tits, L.J., Lohmann, C., et al.The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expressionEur. Heart J.36(1)51-59(2015)